PRQR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders...

Stats
Šios dienos apimtis	228 504
Vidutinė apimtis	204 070
Rinkos kapitalizacija	161.63M
EPS	€0 ( 2024-04-03 )
Kita pelno data	( €-0.120 ) 2024-05-21
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.41
ATR14	€0.0150 (0.75%)

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: 0.74 (moderate)

Signal:(53.792) Neutral

ProQR Therapeutics NV Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ECHO	0.961
SIOX	0.958
MLVF	0.954
IIN	0.95
CDZI	0.949
EXAS	0.942
BTWN	0.94
EXFO	0.934
GDNR	0.933
BKCH	0.932

10 Labiausiai neigiamai susiję koreliacijos
SNPX	-0.971
UTME	-0.963
ISPO	-0.956
PDBC	-0.95
LARK	-0.944
KTTA	-0.943
RIVN	-0.937
OP	-0.936
HMNF	-0.934
PIII	-0.934

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ProQR Therapeutics NV Koreliacija - Valiuta/Žaliavos

0.03
( neutral )

-0.02
( neutral )

0.77
( moderate )

0.20
( neutral )

-0.63
( weak negative )

-0.07
( neutral )

ProQR Therapeutics NV Finansinės ataskaitos

Annual	2023
Pajamos:	€6.38M
Bruto pelnas:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2023
Pajamos:	€6.38M
Bruto pelnas:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2022
Pajamos:	€4.04M
Bruto pelnas:	€1.56M (38.68 %)
EPS:	€-0.910

FY	2021
Pajamos:	€1.35M
Bruto pelnas:	€0.00 (0.00 %)
EPS:	€-1.231

Financial Reports:

No articles found.

ProQR Therapeutics NV

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.